AXSM

The stock has experienced a pullback in the past few months.

Axsome's steady ascent has flipped the script—it now outpaces Moderna in quarterly revenue despite starting from a fraction of its size.

Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AXSM's Auvelity sales surged 54.2% to $333 million in the first half of 2026. New indications could further expand its growth potential.

Axsome Therapeutics has delivered a very strong multi‑year share price run, yet recent pullbacks have many investors asking whether the current valuation can still be supported by its sales.

Axsome Therapeutics, Inc. (NASDAQ:AXSM) and Neurocrine Biosciences, Inc. (NASDAQ:NBIX) have returned -7% and 12% over the past six months, compared to a 21.25% return for the Insider Monkey Billionaire Index and 14% for the State Street SPDR S&P 500 ETF Trust.

Auvelity's Alzheimer's expansion could transform Axsome by 2030.

Axsome is posting 65% revenue growth but burning cash, while Moderna's vaccine market is cooling yet its oncology pipeline carries transformative potential.

Baird Equity Asset Management recently released its “Small/Mid Cap Growth Strategy” second-quarter 2026 investor letter. A copy of the letter can be downloaded here.

Vertex dominates cystic fibrosis with expanding disease coverage and a pipeline entering new therapeutic areas. Axsome is building a commercial drug portfolio quickly but is still working toward consistent profitability.